<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский вестник детской хирургии, анестезиологии и реаниматологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2219-4061</issn><issn publication-format="electronic">2587-6554</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1546</article-id><article-id pub-id-type="doi">10.17816/psaic1546</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Urine metabolome investigation in pediatric urology. Review</article-title><trans-title-group xml:lang="ru"><trans-title>Исследование метаболома мочи в детской урологии. Обзор литературы</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>儿科泌尿学中的尿代谢组研究。文献综述</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5957-7037</contrib-id><contrib-id contrib-id-type="spin">7990-4317</contrib-id><name-alternatives><name xml:lang="en"><surname>Kuzovleva</surname><given-names>Galina I.</given-names></name><name xml:lang="ru"><surname>Кузовлева</surname><given-names>Галина Игоревна</given-names></name><name xml:lang="zh"><surname>Kuzovleva</surname><given-names>Galina I.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><bio xml:lang="zh"><p>MD, Cand. Sci. (Med.)</p></bio><email>dr.gala@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3138-8314</contrib-id><contrib-id contrib-id-type="spin">8290-0356</contrib-id><name-alternatives><name xml:lang="en"><surname>Vlasenko</surname><given-names>Ekaterina Yu.</given-names></name><name xml:lang="ru"><surname>Власенко</surname><given-names>Екатерина Юрьевна</given-names></name><name xml:lang="zh"><surname>Vlasenko</surname><given-names>Ekaterina Yu.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>vlasenko.ekaterina@icloud.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4380-4522</contrib-id><contrib-id contrib-id-type="spin">7725-2499</contrib-id><name-alternatives><name xml:lang="en"><surname>Maltseva</surname><given-names>Larisa D.</given-names></name><name xml:lang="ru"><surname>Мальцева</surname><given-names>Лариса Дмириевна</given-names></name><name xml:lang="zh"><surname>Maltseva</surname><given-names>Larisa D.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><bio xml:lang="zh"><p>MD, Cand. Sci. (Med.)</p></bio><email>lamapost@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2453-1319</contrib-id><contrib-id contrib-id-type="spin">1567-4113</contrib-id><name-alternatives><name xml:lang="en"><surname>Morozova</surname><given-names>Olga L.</given-names></name><name xml:lang="ru"><surname>Морозова</surname><given-names>Ольга Леонидовна</given-names></name><name xml:lang="zh"><surname>Morozova</surname><given-names>Olga L.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д-р мед. наук</p></bio><bio xml:lang="zh"><p>MD, Dr. Sci. (Med.)</p></bio><email>morozova_ol@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)</institution></aff><aff><institution xml:lang="zh">I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Speransky Children’s Hospital No. 9</institution></aff><aff><institution xml:lang="ru">Детская городская клиническая больница № 9 им. Г.Н. Сперанского</institution></aff><aff><institution xml:lang="zh">Speransky Children’s Hospital No. 9</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-12-18" publication-format="electronic"><day>18</day><month>12</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-12-20" publication-format="electronic"><day>20</day><month>12</month><year>2023</year></pub-date><volume>13</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><issue-title xml:lang="zh"/><fpage>551</fpage><lpage>563</lpage><history><date date-type="received" iso-8601-date="2023-08-14"><day>14</day><month>08</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-11-10"><day>10</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Эко-Вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2023,</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://rps-journal.ru/jour/article/view/1546">https://rps-journal.ru/jour/article/view/1546</self-uri><abstract xml:lang="en"><p>Metabolomics is the science of studying small molecules (50–5,000 Da) formed because of the implementation of metabolic pathways in cells and the maintenance of their vital functions. The study of urine metabolome is a promising direction for diagnosing early stages of damage to various cells of the urinary system in pediatric urology, allowing the study of biomarkers or their spectrum, which can improve the identification of existing disorders, and multivariate analysis will provide greater accuracy in making a diagnosis. This study aimed to summarize existing information on urine metabolome and its changes in cases of congenital malformations of the urinary system, accompanied by renal dysplasia, leading to acute kidney injury or chronic kidney disease. A literature search and review was conducted using PubMed, Embase, and Google Scholar. The review presents the possibilities of metabolomic analysis to provide a qualitatively new level of diagnosis and monitoring of damage to the structures of organs and tissues of the urinary system, identifying predictors of pathology progression, and personalized techniques for making medical decisions. However, this method is limited by the high cost of the equipment, need for training of highly qualified personnel, and difficulty in interpreting the results. The study of urine metabolome is very promising for the diagnosis and selection of a timely, rational treatment strategy for children with malformations of the urinary system.</p></abstract><trans-abstract xml:lang="ru"><p>Метаболомика — наука, которая изучает молекулы малого размера (от 50 до 5000 Да), образующиеся в результате реализации метаболических путей процессов в клетках и поддержания их жизнедеятельности. Исследование метаболома мочи — перспективное направление для диагностики ранних этапов повреждения различных клеток мочевыделительной системы в детской урологии, позволяющее исследовать группы биомаркеров или их спектр, что может улучшить выявление имеющихся нарушений, а многомерный анализ обеспечит большую точность при постановке диагноза. Цель исследования — обобщить известную на сегодняшний день информацию о метаболоме мочи и его изменении при врожденных пороках развития мочевой системы, сопровождающихся дисплазией почек и приводящих к острому почечному повреждению или хронической болезни почек. Проведен поиск литературных источников с использованием следующих баз данных: PubMed, Embase и Google Scholar. В обзоре представлены возможности метаболомного анализа для обеспечения качественно нового уровня диагностики и мониторирования повреждения структур органов и тканей мочевой системы, выявления предикторов прогрессирования патологии, а также для персонифицированной тактики принятия врачебных решений. Приведены ограничения данного метода, связанные с дорогостоящим оборудованием, подготовкой высококвалифицированного персонала и сложностью интерпретации результатов. Исследование метаболома мочи очень перспективно в диагностике и выборе своевременной рациональной стратегии лечения детей с пороками развития мочевой системы.</p></trans-abstract><trans-abstract xml:lang="zh"><p>代谢组学是一门研究小分子（50至5000Da）的科学，这些小分子是细胞内实现新陈代谢过程并维持其生命活动的结果。尿代谢组研究是小儿泌尿外科诊断泌尿系统各种细胞早期损伤的一个前景广阔的领域，可以对生物标志物组或其频谱进行研究，从而改进对现有疾病的检测，多维分析将提供更高的诊断准确性。这项研究旨在总结目前已知的尿液代谢组及其在先天性泌尿系统畸形伴有肾发育不良并导致急性肾损伤或慢性肾病时的变化情况。我们使用以下数据库进行了文献检索：PubMed、Embase 和 Google Scholar。这篇综述介绍了代谢组学分析为诊断和监测泌尿系统器官和组织结构的损伤、确定病理进展的预测因子以及个性化医疗决策策略提供新的质量水平的可能性。介绍了这种方法的局限性，包括设备昂贵、需要培训高素质人才以及难以解释结果。尿代谢组的研究在小儿泌尿系畸形的诊断和适时合理治疗策略的选择上是非常有前景的。</p></trans-abstract><kwd-group xml:lang="en"><kwd>urine metabolome</kwd><kwd>mass spectrometry</kwd><kwd>kidney damage</kwd><kwd>congenital uropathy</kwd><kwd>children</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>метаболом мочи</kwd><kwd>масс-спектрометрия</kwd><kwd>повреждение почек</kwd><kwd>врожденная уропатия</kwd><kwd>дети</kwd></kwd-group><kwd-group xml:lang="zh"><kwd>尿液代谢组</kwd><kwd>质谱</kwd><kwd>肾损伤</kwd><kwd>先天性尿病</kwd><kwd>儿童</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Patti GJ, Yanes O, Siuzdak G. Metabolomics: the apogee of the omictriology. Nat Rev Mol Cell Biol. 2012;13(4):263–269. DOI: 10.1038/nrm3314</mixed-citation><mixed-citation xml:lang="ru">Patti G.J., Yanes O., Siuzdak G. Metabolomics: the apogee of the omictriology // Nat Rev Mol Cell Biol. 2012. Vol. 13, No. 4. P. 263–269. DOI:10.1038/nrm3314</mixed-citation><mixed-citation xml:lang="zh">Patti GJ, Yanes O, Siuzdak G. Metabolomics: the apogee of the omictriology. Nat Rev Mol Cell Biol. 2012;13(4):263–269. DOI: 10.1038/nrm3314</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Wishart DS. Metabolomics for investigating physiological and pathophysiological processes. Physiol Rev. 2019;99(4):1819–1875. DOI: 10.1152/physrev.00035.2018</mixed-citation><mixed-citation xml:lang="ru">Wishart D.S. Metabolomics for investigating physiological and pathophysiological processes // Physiol Rev. 2019. Vol. 99, No. 4. P. 1819–1875. DOI: 10.1152/physrev.00035.2018</mixed-citation><mixed-citation xml:lang="zh">Wishart DS. Metabolomics for investigating physiological and pathophysiological processes. Physiol Rev. 2019;99(4):1819–1875. DOI: 10.1152/physrev.00035.2018</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Abbiss H, Maker GL, Trengove RD. Metabolomics approaches for the diagnosis and understanding of kidney diseases. Metabolites. 2019;9(2):34–55. DOI: 10.3390/metabo9020034</mixed-citation><mixed-citation xml:lang="ru">Abbiss H., Maker G.L., Trengove R.D. Metabolomics approaches for the diagnosis and understanding of kidney diseases // Metabolites. 2019. Vol. 9, No. 2. P. 34–55. DOI: 10.3390/metabo9020034</mixed-citation><mixed-citation xml:lang="zh">Abbiss H, Maker GL, Trengove RD. Metabolomics approaches for the diagnosis and understanding of kidney diseases. Metabolites. 2019;9(2):34–55. DOI: 10.3390/metabo9020034</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Khamis MM, Adamko DJ, El-Aneed A. Mass spectrometric based approaches in urine metabolomics and biomarker discovery. Mass Spectrom Rev. 2017;36(2):115–134. DOI: 10.1002/mas.21455</mixed-citation><mixed-citation xml:lang="ru">Khamis M.M., Adamko D.J., El-Aneed A. Mass spectrometric based approaches in urine metabolomics and biomarker discovery // Mass Spectrom Rev. 2017. Vol. 36, No. 2. P. 115–134. DOI: 10.1002/mas.21455</mixed-citation><mixed-citation xml:lang="zh">Khamis MM, Adamko DJ, El-Aneed A. Mass spectrometric based approaches in urine metabolomics and biomarker discovery. Mass Spectrom Rev. 2017;36(2):115–134. DOI: 10.1002/mas.21455</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Zhang A, Sun H, Wu X, Wang X. Urine metabolomics. Clin Chim Acta. 2012;414:65–69. DOI: 10.1016/j.cca.2012.08.016</mixed-citation><mixed-citation xml:lang="ru">Zhang A., Sun H., Wu X., Wang X. Urine metabolomics // Clin Chim Acta. 2012. Vol. 414. P. 65–69. DOI: 10.1016/j.cca.2012.08.016</mixed-citation><mixed-citation xml:lang="zh">Zhang A, Sun H, Wu X, Wang X. Urine metabolomics. Clin Chim Acta. 2012;414:65–69. DOI: 10.1016/j.cca.2012.08.016</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Chiu C-Y, Yeh K-W, Lin G, et al. Metabolomics reveals dynamic metabolic changes associated with age in early childhood. PLoS One. 2016;11(2):e0149823. DOI: 10.1371/journal.pone.0149823</mixed-citation><mixed-citation xml:lang="ru">Chiu C.-Y., Yeh K.-W., Lin G., et al. Metabolomics reveals dynamic metabolic changes associated with age in early childhood // PLoS One. 2016. Vol. 11, No. 2. ID e0149823. DOI: 10.1371/journal.pone.0149823</mixed-citation><mixed-citation xml:lang="zh">Chiu C-Y, Yeh K-W, Lin G, et al. Metabolomics reveals dynamic metabolic changes associated with age in early childhood. PLoS One. 2016;11(2):e0149823. DOI: 10.1371/journal.pone.0149823</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Stankovic AK, DiLauri E. Quality improvements in the preanalytical phase: Focus on urine specimen workflow. Clin Lab Med. 2008;28(2):339–350. DOI: 10.1016/j.cll.2007.12.011</mixed-citation><mixed-citation xml:lang="ru">Stankovic A.K., DiLauri E. Quality improvements in the preanalytical phase: Focus on urine specimen workflow // Clin Lab Med. 2008. Vol. 28, No. 2. P. 339–350. DOI: 10.1016/j.cll.2007.12.011</mixed-citation><mixed-citation xml:lang="zh">Stankovic AK, DiLauri E. Quality improvements in the preanalytical phase: Focus on urine specimen workflow. Clin Lab Med. 2008;28(2):339–350. DOI: 10.1016/j.cll.2007.12.011</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Wang X, Gu H, Palma-Duran SA, et al. Influence of storage conditions and preservatives on metabolite fingerprints in urine. Metabolites. 2019;9(10):203–215. DOI: 10.3390/metabo9100203</mixed-citation><mixed-citation xml:lang="ru">Wang X., Gu H., Palma-Duran S.A., et al. Influence of storage conditions and preservatives on metabolite fingerprints in urine // Metabolites. 2019. Vol. 9, No. 10. P. 203–215. DOI: 10.3390/metabo9100203</mixed-citation><mixed-citation xml:lang="zh">Wang X, Gu H, Palma-Duran SA, et al. Influence of storage conditions and preservatives on metabolite fingerprints in urine. Metabolites. 2019;9(10):203–215. DOI: 10.3390/metabo9100203</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis. Biochem Med (Zagreb). 2014;24(1):89–104. DOI: 10.11613/BM.2014.011</mixed-citation><mixed-citation xml:lang="ru">Delanghe J., Speeckaert M. Preanalytical requirements of urinalysis // Biochem Med (Zagreb). 2014. Vol. 24, No. 1. P. 89–104. DOI: 10.11613/BM.2014.011</mixed-citation><mixed-citation xml:lang="zh">Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis. Biochem Med (Zagreb). 2014;24(1):89–104. DOI: 10.11613/BM.2014.011</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Rodríguez-Morató J, Pozo ÓJ, Marcos J. Targeting human urinary metabolome by LC-MS/MS: a review. Bioanalysis. 2018;10(7):489–516. DOI: 10.4155/bio-2017-0285</mixed-citation><mixed-citation xml:lang="ru">Rodríguez-Morató J., Pozo Ó.J., Marcos J. Targeting human urinary metabolome by LC-MS/MS: a review // Bioanalysis. 2018. Vol. 10, No. 7. P. 489–516. DOI: 10.4155/bio-2017-0285</mixed-citation><mixed-citation xml:lang="zh">Rodríguez-Morató J, Pozo ÓJ, Marcos J. Targeting human urinary metabolome by LC-MS/MS: a review. Bioanalysis. 2018;10(7):489–516. DOI: 10.4155/bio-2017-0285</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Dunn WB, Broadhurst D, Ellis DI, et al. A GC-TOF-MS study of the stability of serum and urine metabolomes during the UK Biobank sample collection and preparation protocols. Int J Epidemiol. 2008;37(S1):i23–i30. DOI: 10.1093/ije/dym281</mixed-citation><mixed-citation xml:lang="ru">Dunn W.B., Broadhurst D., Ellis D.I., et al. A GC-TOF-MS study of the stability of serum and urine metabolomes during the UK Biobank sample collection and preparation protocols // Int J Epidemiol. 2008. Vol. 37, No. S1. P. i23–i30. DOI: 10.1093/ije/dym281</mixed-citation><mixed-citation xml:lang="zh">Dunn WB, Broadhurst D, Ellis DI, et al. A GC-TOF-MS study of the stability of serum and urine metabolomes during the UK Biobank sample collection and preparation protocols. Int J Epidemiol. 2008;37(S1):i23–i30. DOI: 10.1093/ije/dym281</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Laparre J, Kaabia Z, Mooney M, et al. Impact of storage conditions on the urinary metabolomics fingerprint. Anal Chim Acta. 2017;951:99–107. DOI: 10.1016/j.aca.2016.11.055</mixed-citation><mixed-citation xml:lang="ru">Laparre J., Kaabia Z., Mooney M., et al. Impact of storage conditions on the urinary metabolomics fingerprint // Anal Chim Acta. 2017. Vol. 951. P. 99–107. DOI: 10.1016/j.aca.2016.11.055</mixed-citation><mixed-citation xml:lang="zh">Laparre J, Kaabia Z, Mooney M, et al. Impact of storage conditions on the urinary metabolomics fingerprint. Anal Chim Acta. 2017;951:99–107. DOI: 10.1016/j.aca.2016.11.055</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Chaleckis R, Meister I, Zhang P, Wheelock CE. Challenges, progress and promises of metabolite annotation for LC-MS-based metabolomics. Curr Opin Biotechnol. 2019;55:44–50. DOI: 10.1016/j.copbio.2018.07.010</mixed-citation><mixed-citation xml:lang="ru">Chaleckis R., Meister I., Zhang P., Wheelock C.E. Challenges, progress and promises of metabolite annotation for LC-MS-based metabolomics // Curr Opin Biotechnol. 2019. Vol. 55. P. 44–50. DOI: 10.1016/j.copbio.2018.07.010</mixed-citation><mixed-citation xml:lang="zh">Chaleckis R, Meister I, Zhang P, Wheelock CE. Challenges, progress and promises of metabolite annotation for LC-MS-based metabolomics. Curr Opin Biotechnol. 2019;55:44–50. DOI: 10.1016/j.copbio.2018.07.010</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Bartel J, Krumsiek J, Theis FJ. Statistical methods for the analysis of high-throughput metabolomics data. Comput Struct Biotechnol J. 2013;4(5):e201301009. DOI: 10.5936/csbj.201301009</mixed-citation><mixed-citation xml:lang="ru">Bartel J., Krumsiek J., Theis F.J. Statistical methods for the analysis of high-throughput metabolomics data // Comput Struct Biotechnol J. 2013. Vol. 4, No. 5. ID e201301009. DOI: 10.5936/csbj.201301009</mixed-citation><mixed-citation xml:lang="zh">Bartel J, Krumsiek J, Theis FJ. Statistical methods for the analysis of high-throughput metabolomics data. Comput Struct Biotechnol J. 2013;4(5):e201301009. DOI: 10.5936/csbj.201301009</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Wishart DS, Knox C, Guo AC, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 2009;37(S1):D603–D610. DOI: 10.1093/nar/gkn810</mixed-citation><mixed-citation xml:lang="ru">Wishart D.S., Knox C., Guo A.C., et al. HMDB: a knowledgebase for the human metabolome // Nucleic Acids Res. 2009. Vol. 37, No. S1. P. D603–D610. DOI: 10.1093/nar/gkn810</mixed-citation><mixed-citation xml:lang="zh">Wishart DS, Knox C, Guo AC, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 2009;37(S1):D603–D610. DOI: 10.1093/nar/gkn810</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Smith CA, O’Maille G, Want EJ, et al. METLIN: a metabolite mass spectral database. Ther Drug Monit. 2005;27(6):747–751. DOI: 10.1097/01.ftd.0000179845.53213.39</mixed-citation><mixed-citation xml:lang="ru">Smith C.A., O’Maille G., Want E.J., et al. METLIN: a metabolite mass spectral database // Ther Drug Monit. 2005. Vol. 27, No. 6. P. 747–751. DOI: 10.1097/01.ftd.0000179845.53213.39</mixed-citation><mixed-citation xml:lang="zh">Smith CA, O’Maille G, Want EJ, et al. METLIN: a metabolite mass spectral database. Ther Drug Monit. 2005;27(6):747–751. DOI: 10.1097/01.ftd.0000179845.53213.39</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Bouatra S, Aziat F, Mandal R, et al. The human urine metabolome. PLoS One. 2013;8(9):e73076. DOI: 10.1371/journal.pone.0073076</mixed-citation><mixed-citation xml:lang="ru">Bouatra S., Aziat F., Mandal R., et al. The human urine metabolome // PLoS One. 2013. Vol. 8, No. 9. ID e73076. DOI: 10.1371/journal.pone.0073076</mixed-citation><mixed-citation xml:lang="zh">Bouatra S, Aziat F, Mandal R, et al. The human urine metabolome. PLoS One. 2013;8(9):e73076. DOI: 10.1371/journal.pone.0073076</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Dai X, Shen L. Advances and trends in omics technology development. Front Med (Lausanne). 2022;9:911861. DOI: 10.3389/fmed.2022.911861</mixed-citation><mixed-citation xml:lang="ru">Dai X., Shen L. Advances and trends in omics technology development // Front Med (Lausanne). 2022. Vol. 9. ID 911861. DOI: 10.3389/fmed.2022.911861</mixed-citation><mixed-citation xml:lang="zh">Dai X, Shen L. Advances and trends in omics technology development. Front Med (Lausanne). 2022;9:911861. DOI: 10.3389/fmed.2022.911861</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Bukharina AB, Fedulkina AO, Demidova KN, et al. Omics technologies in screening for kidney disease in children with congenital uropathy. Annals of the Russian academy of medical sciences. 2022;77(5):354–361. (In Russ.) DOI: 10.15690/vramn2107</mixed-citation><mixed-citation xml:lang="ru">Бухарина А.Б., Федулкина А.O., Демидова К.Н., и др. Омиксные технологии в скрининге повреждения почек у детей с врожденными уропатиями // Вестник РАМН. 2022. Т. 77, № 5. С. 354–361. DOI:10.15690/vramn2107</mixed-citation><mixed-citation xml:lang="zh">Bukharina AB, Fedulkina AO, Demidova KN, et al. Omics technologies in screening for kidney disease in children with congenital uropathy. Annals of the Russian academy of medical sciences. 2022;77(5):354–361. (In Russ.) DOI: 10.15690/vramn2107</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Emwas A-H, Roy R, McKay RT, et al. NMR spectroscopy for metabolomics research. Metabolites. 2019;9(7):123. DOI: 10.3390/metabo9070123</mixed-citation><mixed-citation xml:lang="ru">Emwas A.-H., Roy R., McKay R.T., et al. NMR spectroscopy for metabolomics research // Metabolites. 2019. Vol. 9, No. 7. ID 123. DOI: 10.3390/metabo9070123</mixed-citation><mixed-citation xml:lang="zh">Emwas A-H, Roy R, McKay RT, et al. NMR spectroscopy for metabolomics research. Metabolites. 2019;9(7):123. DOI: 10.3390/metabo9070123</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Thomas SN, French D, Jannetto PJ, et al. Liquid chromatography–tandem mass spectrometry for clinical diagnostics. Nat Rev Methods Primers. 2022;2(1):96. DOI: 10.1038/s43586-022-00175-x</mixed-citation><mixed-citation xml:lang="ru">Thomas S.N., French D., Jannetto P.J., et al. Liquid chromatography–tandem mass spectrometry for clinical diagnostics // Nat Rev Methods Primers. 2022. Vol. 2, No. 1. ID 96. DOI: 10.1038/s43586-022-00175-x</mixed-citation><mixed-citation xml:lang="zh">Thomas SN, French D, Jannetto PJ, et al. Liquid chromatography–tandem mass spectrometry for clinical diagnostics. Nat Rev Methods Primers. 2022;2(1):96. DOI: 10.1038/s43586-022-00175-x</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Fiehn O. Metabolomics by gas chromatography-mass spectrometry: combined targeted and untargeted profiling. Curr Protoc Mol Biol. 2016;114(1):30.4.1–30.4.32. DOI: 10.1002/0471142727.mb3004s114</mixed-citation><mixed-citation xml:lang="ru">Fiehn O. Metabolomics by gas chromatography-mass spectrometry: combined targeted and untargeted profiling // Curr Protoc Mol Biol. 2016. Vol. 114, No. 1. P. 30.4.1–30.4.32. DOI: 10.1002/0471142727.mb3004s114</mixed-citation><mixed-citation xml:lang="zh">Fiehn O. Metabolomics by gas chromatography-mass spectrometry: combined targeted and untargeted profiling. Curr Protoc Mol Biol. 2016;114(1):30.4.1–30.4.32. DOI: 10.1002/0471142727.mb3004s114</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Jokiniitty E, Hokkinen L, Kumpulainen P, et al. Urine headspace analysis with field asymmetric ion mobility spectrometry for detection of chronic kidney disease. Biomark Med. 2020;14(8):629–638. DOI: 10.2217/bmm-2020-0085</mixed-citation><mixed-citation xml:lang="ru">Jokiniitty E., Hokkinen L., Kumpulainen P., et al. Urine headspace analysis with field asymmetric ion mobility spectrometry for detection of chronic kidney disease // Biomark Med. 2020. Vol. 14, No. 8. P. 629–638. DOI: 10.2217/bmm-2020-0085</mixed-citation><mixed-citation xml:lang="zh">Jokiniitty E, Hokkinen L, Kumpulainen P, et al. Urine headspace analysis with field asymmetric ion mobility spectrometry for detection of chronic kidney disease. Biomark Med. 2020;14(8):629–638. DOI: 10.2217/bmm-2020-0085</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Fitzgerald J, Fenniri H. Cutting edge methods for non-invasive disease diagnosis using E-tongue and E-nose devices. Biosensors (Basel). 2017;7(4):59. DOI: 10.3390/bios7040059</mixed-citation><mixed-citation xml:lang="ru">Fitzgerald J., Fenniri H. Cutting edge methods for non-invasive disease diagnosis using E-tongue and E-nose devices // Biosensors (Basel). 2017. Vol. 7, No. 4. ID 59. DOI: 10.3390/bios7040059</mixed-citation><mixed-citation xml:lang="zh">Fitzgerald J, Fenniri H. Cutting edge methods for non-invasive disease diagnosis using E-tongue and E-nose devices. Biosensors (Basel). 2017;7(4):59. DOI: 10.3390/bios7040059</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Teruya T, Goga H, Yanagida M. Aging markers in human urine: A comprehensive, non-targeted LC-MS study. FASEB Bioadv. 2020;2(12):720–733. DOI: 10.1096/fba.2020-00047</mixed-citation><mixed-citation xml:lang="ru">Teruya T., Goga H., Yanagida M. Aging markers in human urine: A comprehensive, non-targeted LC-MS study // FASEB Bioadv. 2020. Vol. 2, No. 12. P. 720–733. DOI: 10.1096/fba.2020-00047</mixed-citation><mixed-citation xml:lang="zh">Teruya T, Goga H, Yanagida M. Aging markers in human urine: A comprehensive, non-targeted LC-MS study. FASEB Bioadv. 2020;2(12):720–733. DOI: 10.1096/fba.2020-00047</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Scalabre A, Jobard E, Demède D, et al. Evolution of newborns’ urinary metabolomic profiles according to age and growth. J Proteome Res. 2017;16(10):3732–3740. DOI: 10.1021/acs.jproteome.7b00421</mixed-citation><mixed-citation xml:lang="ru">Scalabre A., Jobard E., Demède D., et al. Evolution of newborns’ urinary metabolomic profiles according to age and growth // J Proteome Res. 2017. Vol. 16, No. 10. P. 3732–3740. DOI: 10.1021/acs.jproteome.7b00421</mixed-citation><mixed-citation xml:lang="zh">Scalabre A, Jobard E, Demède D, et al. Evolution of newborns’ urinary metabolomic profiles according to age and growth. J Proteome Res. 2017;16(10):3732–3740. DOI: 10.1021/acs.jproteome.7b00421</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Liu X, Tian X, Qinghong S, et al. Characterization of LC-MS based urine metabolomics in healthy children and adults. Peer J. 2022;10:e13545. DOI: 10.7717/peerj.13545</mixed-citation><mixed-citation xml:lang="ru">Liu X., Tian X., Qinghong S., et al. Characterization of LC-MS based urine metabolomics in healthy children and adults // Peer J. 2022. Vol. 10. ID e13545. DOI: 10.7717/peerj.13545</mixed-citation><mixed-citation xml:lang="zh">Liu X, Tian X, Qinghong S, et al. Characterization of LC-MS based urine metabolomics in healthy children and adults. Peer J. 2022;10:e13545. DOI: 10.7717/peerj.13545</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Reusch JEB, Kumar TR, Regensteiner JG, Zeitler PS. Conference participants. Identifying the critical gaps in research on sex differences in metabolism across the life span. Endocrinology. 2018;159(1):9–19. DOI: 10.1210/en.2017-03019</mixed-citation><mixed-citation xml:lang="ru">Reusch J.E.B., Kumar T.R., Regensteiner J.G., Zeitler P.S. Conference participants. identifying the critical gaps in research on sex differences in metabolism across the life span // Endocrinology. 2018. Vol. 159, No. 1. P. 9–19. DOI: 10.1210/en.2017-03019</mixed-citation><mixed-citation xml:lang="zh">Reusch JEB, Kumar TR, Regensteiner JG, Zeitler PS. Conference participants. Identifying the critical gaps in research on sex differences in metabolism across the life span. Endocrinology. 2018;159(1):9–19. DOI: 10.1210/en.2017-03019</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Tang WHW, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–1584. DOI: 10.1056/NEJMoa1109400</mixed-citation><mixed-citation xml:lang="ru">Tang W.H.W., Wang Z., Levison B.S., et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk // N Engl J Med. 2013. Vol. 368, No. 17. P. 1575–1584. DOI: 10.1056/NEJMoa1109400</mixed-citation><mixed-citation xml:lang="zh">Tang WHW, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–1584. DOI: 10.1056/NEJMoa1109400</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–585. DOI: 10.1038/nm.3145.</mixed-citation><mixed-citation xml:lang="ru">Koeth R.A., Wang Z., Levison B.S., et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis // Nat Med. 2013. Vol. 19, No. 5. P. 576–585. DOI: 10.1038/nm.3145.</mixed-citation><mixed-citation xml:lang="zh">Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–585. DOI: 10.1038/nm.3145.</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Wilson Tang WH, Wang Z, Kennedy DJ, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448–455. DOI: 10.1161/CIRCRESAHA.116.305360</mixed-citation><mixed-citation xml:lang="ru">Wilson Tang W.H., Wang Z., Kennedy D.J., et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease // Circ Res. 2015. Vol. 116, No. 3. P. 448–455. DOI: 10.1161/CIRCRESAHA.116.305360</mixed-citation><mixed-citation xml:lang="zh">Wilson Tang WH, Wang Z, Kennedy DJ, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448–455. DOI: 10.1161/CIRCRESAHA.116.305360</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Liu X, Yin P, Shao Y, et al. Which is the urine sample material of choice for metabolomics-driven biomarker studies? Anal Chim Acta. 2020;1105:120–127. DOI: 10.1016/j.aca.2020.01.028</mixed-citation><mixed-citation xml:lang="ru">Liu X., Yin P., Shao Y., et al. Which is the urine sample material of choice for metabolomics-driven biomarker studies? // Anal Chim Acta. 2020. Vol. 1105. P. 120–127. DOI: 10.1016/j.aca.2020.01.028</mixed-citation><mixed-citation xml:lang="zh">Liu X, Yin P, Shao Y, et al. Which is the urine sample material of choice for metabolomics-driven biomarker studies? Anal Chim Acta. 2020;1105:120–127. DOI: 10.1016/j.aca.2020.01.028</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Liu Z, Xia B, Saric J, et al. Effects of vancomycin and ciprofloxacin on the NMRI mouse metabolism. J Proteome Res. 2018;17(10):3565–3573. DOI: 10.1021/acs.jproteome.8b00583</mixed-citation><mixed-citation xml:lang="ru">Liu Z., Xia B., Saric J., et al. Effects of vancomycin and ciprofloxacin on the NMRI mouse metabolism // J Proteome Res. 2018. Vol. 17, No. 10. P. 3565–3573. DOI: 10.1021/acs.jproteome.8b00583</mixed-citation><mixed-citation xml:lang="zh">Liu Z, Xia B, Saric J, et al. Effects of vancomycin and ciprofloxacin on the NMRI mouse metabolism. J Proteome Res. 2018;17(10):3565–3573. DOI: 10.1021/acs.jproteome.8b00583</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">Kim AHJ, Lee Y, Kim E, et al. Assessment of oral vancomycin-induced alterations in gut bacterial microbiota and metabolome of healthy men. Front Cell Infect Microbiol. 2021;11:629438. DOI: 10.3389/fcimb.2021.629438</mixed-citation><mixed-citation xml:lang="ru">Kim A.H.J., Lee Y., Kim E., et al. Assessment of oral vancomycin-induced alterations in gut bacterial microbiota and metabolome of healthy men // Front Cell Infect Microbiol. 2021. Vol. 11. ID 629438. DOI: 10.3389/fcimb.2021.629438</mixed-citation><mixed-citation xml:lang="zh">Kim AHJ, Lee Y, Kim E, et al. Assessment of oral vancomycin-induced alterations in gut bacterial microbiota and metabolome of healthy men. Front Cell Infect Microbiol. 2021;11:629438. DOI: 10.3389/fcimb.2021.629438</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">Rodriguez MM. Congenital anomalies of the kidney and the urinary tract (CAKUT). Fetal PediatrPathol. 2014;33(5-6):293–320. DOI: 10.3109/15513815.2014.959678</mixed-citation><mixed-citation xml:lang="ru">Rodriguez M.M. Congenital anomalies of the kidney and the urinary tract (CAKUT) // Fetal Pediatr Pathol. 2014. Vol. 33, No. 5-6. P. 293–320. DOI: 10.3109/15513815.2014.959678</mixed-citation><mixed-citation xml:lang="zh">Rodriguez MM. Congenital anomalies of the kidney and the urinary tract (CAKUT). Fetal PediatrPathol. 2014;33(5-6):293–320. DOI: 10.3109/15513815.2014.959678</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">Macioszek S, Wawrzyniak R, Kranz A, et al. Comprehensive metabolic signature of renal dysplasia in children. A multiplatform metabolomics concept. Front Mol Biosci. 2021;8:665661. DOI: 10.3389/fmolb.2021.665661</mixed-citation><mixed-citation xml:lang="ru">Macioszek S., Wawrzyniak R., Kranz A., et al. Comprehensive metabolic signature of renal dysplasia in children. A multiplatform metabolomics concept // Front Mol Biosci. 2021. Vol. 8. ID 665661. DOI: 10.3389/fmolb.2021.665661</mixed-citation><mixed-citation xml:lang="zh">Macioszek S, Wawrzyniak R, Kranz A, et al. Comprehensive metabolic signature of renal dysplasia in children. A multiplatform metabolomics concept. Front Mol Biosci. 2021;8:665661. DOI: 10.3389/fmolb.2021.665661</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">Xu X, Nie S, Zhang A, et al. Acute kidney injury among hospitalized children in China. Clin J Am Soc Nephrol. 2018;13(12):1791–1800. DOI: 10.2215/CJN.00800118</mixed-citation><mixed-citation xml:lang="ru">Xu X., Nie S., Zhang A., et al. Acute kidney injury among hospitalized children in China // Clin J Am Soc Nephrol. 2018. Vol. 13, No. 12. P. 1791–1800. DOI: 10.2215/CJN.00800118</mixed-citation><mixed-citation xml:lang="zh">Xu X, Nie S, Zhang A, et al. Acute kidney injury among hospitalized children in China. Clin J Am Soc Nephrol. 2018;13(12):1791–1800. DOI: 10.2215/CJN.00800118</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">Sutherland SM, Ji J, Sheikhi FH, et al. AKI in hospitalized children: Epidemiology and clinical associations in a national cohort. Clin J Am Soc Nephrol. 2013;8(10):1661–1669. DOI: 10.2215/CJN.00270113</mixed-citation><mixed-citation xml:lang="ru">Sutherland S.M., Ji J., Sheikhi F.H., et al. AKI in hospitalized children: Epidemiology and clinical associations in a national cohort // Clin J Am Soc Nephrol. 2013. Vol. 8, No. 10. P. 1661–1669. DOI: 10.2215/CJN.00270113</mixed-citation><mixed-citation xml:lang="zh">Sutherland SM, Ji J, Sheikhi FH, et al. AKI in hospitalized children: Epidemiology and clinical associations in a national cohort. Clin J Am Soc Nephrol. 2013;8(10):1661–1669. DOI: 10.2215/CJN.00270113</mixed-citation></citation-alternatives></ref><ref id="B39"><label>39.</label><citation-alternatives><mixed-citation xml:lang="en">Andreoli SP. Acute kidney injury in children. Pediatr Nephrol. 2009;24(2):253–263. DOI: 10.1007/s00467-008-1074-9</mixed-citation><mixed-citation xml:lang="ru">Andreoli S.P. Acute kidney injury in children // Pediatr Nephrol. 2009. Vol. 24, No. 2. P. 253–263. DOI: 10.1007/s00467-008-1074-9</mixed-citation><mixed-citation xml:lang="zh">Andreoli SP. Acute kidney injury in children. Pediatr Nephrol. 2009;24(2):253–263. DOI: 10.1007/s00467-008-1074-9</mixed-citation></citation-alternatives></ref><ref id="B40"><label>40.</label><citation-alternatives><mixed-citation xml:lang="en">Cleto-Yamane TL, Gomes CLR, Suassuna JHR, Nogueira PK. Acute kidney injury epidemiology in pediatrics. J Bras Nefrol. 2019;41(2):275–283. DOI: 10.1590/2175-8239-JBN-2018-0127</mixed-citation><mixed-citation xml:lang="ru">Cleto-Yamane T.L., Gomes C.L.R., Suassuna J.H.R., Nogueira P.K. Acute kidney injury epidemiology in pediatrics // J Bras Nefrol. 2019. Vol. 41, No. 2. P. 275–283. DOI: 10.1590/2175-8239-JBN-2018-0127</mixed-citation><mixed-citation xml:lang="zh">Cleto-Yamane TL, Gomes CLR, Suassuna JHR, Nogueira PK. Acute kidney injury epidemiology in pediatrics. J Bras Nefrol. 2019;41(2):275–283. DOI: 10.1590/2175-8239-JBN-2018-0127</mixed-citation></citation-alternatives></ref><ref id="B41"><label>41.</label><citation-alternatives><mixed-citation xml:lang="en">Mammen C, Abbas AA, Skippen P, et al. Long-term risk of CKD in children surviving episodes of acute kidney injury in the intensive care unit: A prospective cohort study. Am J Kidney Dis. 2012;59(4):523–530. DOI: 10.1053/j.ajkd.2011.10.048</mixed-citation><mixed-citation xml:lang="ru">Mammen C., Abbas A.A., Skippen P., et al. Long-term risk of CKD in children surviving episodes of acute kidney injury in the intensive care unit: A prospective cohort study // Am J Kidney Dis. 2012. Vol. 59, No. 4. P. 523–530. DOI: 10.1053/j.ajkd.2011.10.048</mixed-citation><mixed-citation xml:lang="zh">Mammen C, Abbas AA, Skippen P, et al. Long-term risk of CKD in children surviving episodes of acute kidney injury in the intensive care unit: A prospective cohort study. Am J Kidney Dis. 2012;59(4):523–530. DOI: 10.1053/j.ajkd.2011.10.048</mixed-citation></citation-alternatives></ref><ref id="B42"><label>42.</label><citation-alternatives><mixed-citation xml:lang="en">Beger RD, Holland RD, Sun J, et al. Metabonomics of acute kidney injury in children after cardiac surgery. Pediatr Nephrol. 2008;23(6):977–984. DOI: 10.1007/s00467-008-0756-7</mixed-citation><mixed-citation xml:lang="ru">Beger R.D., Holland R.D., Sun J., et al. Metabonomics of acute kidney injury in children after cardiac surgery // Pediatr Nephrol. 2008. Vol. 23, No. 6. P. 977–984. DOI: 10.1007/s00467-008-0756-7</mixed-citation><mixed-citation xml:lang="zh">Beger RD, Holland RD, Sun J, et al. Metabonomics of acute kidney injury in children after cardiac surgery. Pediatr Nephrol. 2008;23(6):977–984. DOI: 10.1007/s00467-008-0756-7</mixed-citation></citation-alternatives></ref><ref id="B43"><label>43.</label><citation-alternatives><mixed-citation xml:lang="en">Muhle-Goll C, Eisenmann P, Luy B, et al. Urinary NMR profiling in pediatric acute kidney injury — a pilot study. Int J Mol Sci. 2020;21(4):1187. DOI: 10.3390/ijms21041187</mixed-citation><mixed-citation xml:lang="ru">Muhle-Goll C., Eisenmann P., Luy B., et al. Urinary NMR profiling in pediatric acute kidney injury — a pilot study // Int J Mol Sci. 2020. Vol. 21, No. 4. ID 1187. DOI: 10.3390/ijms21041187</mixed-citation><mixed-citation xml:lang="zh">Muhle-Goll C, Eisenmann P, Luy B, et al. Urinary NMR profiling in pediatric acute kidney injury — a pilot study. Int J Mol Sci. 2020;21(4):1187. DOI: 10.3390/ijms21041187</mixed-citation></citation-alternatives></ref><ref id="B44"><label>44.</label><citation-alternatives><mixed-citation xml:lang="en">Viau A, El Karoui K, Laouari D, et al. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest. 2010;120(11):4065–4076. DOI: 10.1172/JCI42004</mixed-citation><mixed-citation xml:lang="ru">Viau A., El Karoui K., Laouari D., et al. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans // J Clin Invest. 2010. Vol. 120, No. 11. P. 4065–4076. DOI: 10.1172/JCI42004</mixed-citation><mixed-citation xml:lang="zh">Viau A, El Karoui K, Laouari D, et al. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest. 2010;120(11):4065–4076. DOI: 10.1172/JCI42004</mixed-citation></citation-alternatives></ref><ref id="B45"><label>45.</label><citation-alternatives><mixed-citation xml:lang="en">Harambat J, van Stralen KJ, Kim JJ, Tizard EJ. Epidemiology of chronic kidney disease in children. Pediatr Nephrol. 2012;27(3):363–373. DOI: 10.1007/s00467-011-1939-1</mixed-citation><mixed-citation xml:lang="ru">Harambat J., van Stralen K.J., Kim J.J., Tizard E.J. Epidemiology of chronic kidney disease in children // Pediatr Nephrol. 2012. Vol. 27, No. 3. P. 363–373. DOI: 10.1007/s00467-011-1939-1</mixed-citation><mixed-citation xml:lang="zh">Harambat J, van Stralen KJ, Kim JJ, Tizard EJ. Epidemiology of chronic kidney disease in children. Pediatr Nephrol. 2012;27(3):363–373. DOI: 10.1007/s00467-011-1939-1</mixed-citation></citation-alternatives></ref><ref id="B46"><label>46.</label><citation-alternatives><mixed-citation xml:lang="en">Becherucci F, Roperto RM, Materassi M, Romagnani P. Chronic kidney disease in children. Clin Kidney J. 2016;9(4):583–591. DOI: 10.1093/ckj/sfw047</mixed-citation><mixed-citation xml:lang="ru">Becherucci F., Roperto R.M., Materassi M., Romagnani P. Chronic kidney disease in children // Clin Kidney J. 2016. Vol. 9, No. 4. P. 583–591. DOI: 10.1093/ckj/sfw047</mixed-citation><mixed-citation xml:lang="zh">Becherucci F, Roperto RM, Materassi M, Romagnani P. Chronic kidney disease in children. Clin Kidney J. 2016;9(4):583–591. DOI: 10.1093/ckj/sfw047</mixed-citation></citation-alternatives></ref><ref id="B47"><label>47.</label><citation-alternatives><mixed-citation xml:lang="en">Vivante A, Hildebrandt F. Exploring the genetic basis of early-onset chronic kidney disease. Nat Rev Nephrol. 2016;12(3):133–146. DOI: 10.1038/nrneph.2015.205</mixed-citation><mixed-citation xml:lang="ru">Vivante A., Hildebrandt F. Exploring the genetic basis of early-onset chronic kidney disease // Nat Rev Nephrol. 2016. Vol. 12, No. 3. P. 133–146. DOI: 10.1038/nrneph.2015.205</mixed-citation><mixed-citation xml:lang="zh">Vivante A, Hildebrandt F. Exploring the genetic basis of early-onset chronic kidney disease. Nat Rev Nephrol. 2016;12(3):133–146. DOI: 10.1038/nrneph.2015.205</mixed-citation></citation-alternatives></ref><ref id="B48"><label>48.</label><citation-alternatives><mixed-citation xml:lang="en">Martens-Lobenhoffer J, Bode-Böger SM. Amino acid N-acetylation: Metabolic elimination of symmetric dimethylarginine as symmetric Nα-acetyldimethylarginine, determined in human plasma and urine by LC–MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;975:59–64. DOI: 10.1016/j.jchromb.2014.11.009</mixed-citation><mixed-citation xml:lang="ru">Martens-Lobenhoffer J., Bode-Böger S.M. Amino acid N-acetylation: Metabolic elimination of symmetric dimethylarginine as symmetric Nα-acetyldimethylarginine, determined in human plasma and urine by LC–MS/MS // J Chromatogr B Analyt Technol Biomed Life Sci. 2015. Vol. 975. P. 59–64. DOI: 10.1016/j.jchromb.2014.11.009</mixed-citation><mixed-citation xml:lang="zh">Martens-Lobenhoffer J, Bode-Böger SM. Amino acid N-acetylation: Metabolic elimination of symmetric dimethylarginine as symmetric Nα-acetyldimethylarginine, determined in human plasma and urine by LC–MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;975:59–64. DOI: 10.1016/j.jchromb.2014.11.009</mixed-citation></citation-alternatives></ref><ref id="B49"><label>49.</label><citation-alternatives><mixed-citation xml:lang="en">Benito S, Sánchez A, Unceta N, et al. LC-QTOF-MS-based targeted metabolomics of arginine-creatine metabolic pathway-related compounds in plasma: application to identify potential biomarkers in pediatric chronic kidney disease. Anal Bioanal Chem. 2016;408(3):747–760. DOI: 10.1007/s00216-015-9153-9</mixed-citation><mixed-citation xml:lang="ru">Benito S., Sánchez A., Unceta N., et al. LC-QTOF-MS-based targeted metabolomics of arginine-creatine metabolic pathway-related compounds in plasma: application to identify potential biomarkers in pediatric chronic kidney disease // Anal Bioanal Chem. 2016. Vol. 408, No. 3. P. 747–760. DOI: 10.1007/s00216-015-9153-9</mixed-citation><mixed-citation xml:lang="zh">Benito S, Sánchez A, Unceta N, et al. LC-QTOF-MS-based targeted metabolomics of arginine-creatine metabolic pathway-related compounds in plasma: application to identify potential biomarkers in pediatric chronic kidney disease. Anal Bioanal Chem. 2016;408(3):747–760. DOI: 10.1007/s00216-015-9153-9</mixed-citation></citation-alternatives></ref><ref id="B50"><label>50.</label><citation-alternatives><mixed-citation xml:lang="en">Zhang W, Miikeda A, Zuckerman J, et al. Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice. Sci Rep. 2021;11(10):518. DOI: 10.1038/s41598-020-80063-0</mixed-citation><mixed-citation xml:lang="ru">Zhang W., Miikeda A., Zuckerman J., et al. Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice // Sci Rep. 2021. Vol. 11, No. 1. ID 518. DOI: 10.1038/s41598-020-80063-0</mixed-citation><mixed-citation xml:lang="zh">Zhang W, Miikeda A, Zuckerman J, et al. Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice. Sci Rep. 2021;11(10):518. DOI: 10.1038/s41598-020-80063-0</mixed-citation></citation-alternatives></ref><ref id="B51"><label>51.</label><citation-alternatives><mixed-citation xml:lang="en">Wang Y-N, Ma S-X, Chen Y-Y, et al. Chronic kidney disease: Biomarker diagnosis to therapeutic targets. Clin Chim Acta. 2019;499:54–63. DOI: 10.1016/j.cca.2019.08.030</mixed-citation><mixed-citation xml:lang="ru">Wang Y.-N., Ma S.-X., Chen Y.-Y., et al. Chronic kidney disease: Biomarker diagnosis to therapeutic targets // Clin Chim Acta. 2019. Vol. 499. P. 54–63. DOI: 10.1016/j.cca.2019.08.030</mixed-citation><mixed-citation xml:lang="zh">Wang Y-N, Ma S-X, Chen Y-Y, et al. Chronic kidney disease: Biomarker diagnosis to therapeutic targets. Clin Chim Acta. 2019;499:54–63. DOI: 10.1016/j.cca.2019.08.030</mixed-citation></citation-alternatives></ref><ref id="B52"><label>52.</label><citation-alternatives><mixed-citation xml:lang="en">Mattoo TK. Vesicoureteral reflux and reflux nephropathy, advances in chronic kidney disease. Adv Chronic Kidney Dis. 2011;18(5):348–354. DOI: 10.1053/j.ackd.2011.07.006</mixed-citation><mixed-citation xml:lang="ru">Mattoo T.K. Vesicoureteral reflux and reflux nephropathy, advances in chronic kidney disease // Adv Chronic Kidney Dis. 2011. Vol. 18, No. 5. P. 348–354. DOI: 10.1053/j.ackd.2011.07.006</mixed-citation><mixed-citation xml:lang="zh">Mattoo TK. Vesicoureteral reflux and reflux nephropathy, advances in chronic kidney disease. Adv Chronic Kidney Dis. 2011;18(5):348–354. DOI: 10.1053/j.ackd.2011.07.006</mixed-citation></citation-alternatives></ref><ref id="B53"><label>53.</label><citation-alternatives><mixed-citation xml:lang="en">Läckgren G, Cooper CS, Neveus T, Kirsch AJ. Management of vesicoureteral reflux: What have we learned over the last 20 years? Front Pediatr. 2021;9:650326. DOI: 10.3389/fped.2021.650326</mixed-citation><mixed-citation xml:lang="ru">Läckgren G., Cooper C.S., Neveus T., Kirsch A.J. Management of vesicoureteral reflux: What have we learned over the last 20 years? // Front Pediatr. 2021. Vol. 9. ID 650326. DOI: 10.3389/fped.2021.650326</mixed-citation><mixed-citation xml:lang="zh">Läckgren G, Cooper CS, Neveus T, Kirsch AJ. Management of vesicoureteral reflux: What have we learned over the last 20 years? Front Pediatr. 2021;9:650326. DOI: 10.3389/fped.2021.650326</mixed-citation></citation-alternatives></ref><ref id="B54"><label>54.</label><citation-alternatives><mixed-citation xml:lang="en">Vitko D, McQuaid JW, Gheinani AH, et al. Urinary tract infections in children with vesicoureteral reflux are accompanied by alterations in urinary microbiota and metabolome profiles. Eur Urol. 2022;81(2):151–154. DOI: 10.1016/j.eururo.2021.08.022</mixed-citation><mixed-citation xml:lang="ru">Vitko D., McQuaid J.W., Gheinani A.H., et al. Urinary tract infections in children with vesicoureteral reflux are accompanied by alterations in urinary microbiota and metabolome profiles // Eur Urol. 2022. Vol. 81, No. 2. P. 151–154. DOI: 10.1016/j.eururo.2021.08.022</mixed-citation><mixed-citation xml:lang="zh">Vitko D, McQuaid JW, Gheinani AH, et al. Urinary tract infections in children with vesicoureteral reflux are accompanied by alterations in urinary microbiota and metabolome profiles. Eur Urol. 2022;81(2):151–154. DOI: 10.1016/j.eururo.2021.08.022</mixed-citation></citation-alternatives></ref><ref id="B55"><label>55.</label><citation-alternatives><mixed-citation xml:lang="en">Riccio S, Valentino MS, Passaro AP, et al. New insights from metabolomics in pediatric renal diseases. Children (Basel). 2022;9(1):118. DOI: 10.3390/children9010118</mixed-citation><mixed-citation xml:lang="ru">Riccio S., Valentino M.S., Passaro A.P., et al. New insights from metabolomics in pediatric renal diseases // Children (Basel). 2022. Vol. 9, No.1. ID 118. DOI: 10.3390/children9010118</mixed-citation><mixed-citation xml:lang="zh">Riccio S, Valentino MS, Passaro AP, et al. New insights from metabolomics in pediatric renal diseases. Children (Basel). 2022;9(1):118. DOI: 10.3390/children9010118</mixed-citation></citation-alternatives></ref><ref id="B56"><label>56.</label><citation-alternatives><mixed-citation xml:lang="en">Morozova O, Morozov D, Pervouchine D, et al. Urinary biomarkers of latent inflammation and fibrosis in children with vesicoureteral reflux. Int Urol Nephrol. 2020;52(4):603–610. DOI: 10.1007/s11255-019-02357-1</mixed-citation><mixed-citation xml:lang="ru">Morozova O., Morozov D., Pervouchine D., et al. Urinary biomarkers of latent inflammation and fibrosis in children with vesicoureteral reflux // Int Urol Nephrol. 2020. Vol. 52, No. 4. P. 603–610. DOI: 10.1007/s11255-019-02357-1</mixed-citation><mixed-citation xml:lang="zh">Morozova O, Morozov D, Pervouchine D, et al. Urinary biomarkers of latent inflammation and fibrosis in children with vesicoureteral reflux. Int Urol Nephrol. 2020;52(4):603–610. DOI: 10.1007/s11255-019-02357-1</mixed-citation></citation-alternatives></ref></ref-list></back></article>
